<List><item><source>MED</source><extId>28396468</extId><pmcid>PMC5394635</pmcid><annotations><annotation><prefix>V GP, nucleoprotein)</prefix><exact>NCT00072605</exact><postfix>November 20032, 4 or</postfix><tags><tag><name>NCT00072605</name><uri>http://identifiers.org/clinicaltrials/NCT00072605</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-4f37ad50e781a20f578be71c554837e0</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> glu at position 71)</prefix><exact>NCT00374309</exact><postfix>September 20062 × 1</postfix><tags><tag><name>NCT00374309</name><uri>http://identifiers.org/clinicaltrials/NCT00374309</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-ea522980e4d10e585d2a456d5becef0c</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> (full-length WT GP)</prefix><exact>NCT00605514</exact><postfix>January 20084 mgthre</postfix><tags><tag><name>NCT00605514</name><uri>http://identifiers.org/clinicaltrials/NCT00605514</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-ebeccc5118c93bf3764a41c69864c80a</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> (full-length WT GP)</prefix><exact>NCT00997607</exact><postfix>November 20094 mgthr</postfix><tags><tag><name>NCT00997607</name><uri>http://identifiers.org/clinicaltrials/NCT00997607</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-b39d6d1793603b154b8130d60a76933f</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>Ad3 EBOV and SUDV GP</prefix><exact>NCT02231866</exact><postfix>September 20141 × 1</postfix><tags><tag><name>NCT02231866</name><uri>http://identifiers.org/clinicaltrials/NCT02231866</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-8d4881ec77f250713ebb2e9d6dc91f5a</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> vectorChAd3 EBOV GP</prefix><exact>NCT02240875</exact><postfix>September 20141 × 1</postfix><tags><tag><name>NCT02240875</name><uri>http://identifiers.org/clinicaltrials/NCT02240875</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-38f347dfc81cf26f4151c05ee3f389a2</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>V GP and MVA-BN Filo</prefix><exact>NCT02240875</exact><postfix>September 2014ChAd3 </postfix><tags><tag><name>NCT02240875</name><uri>http://identifiers.org/clinicaltrials/NCT02240875</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-f4962235c97b3619bb5d4f83b157b972</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>al vaccinerVSV-ZEBOV</prefix><exact>NCT02269423</exact><postfix>NCT02280408 October</postfix><tags><tag><name>NCT02269423</name><uri>http://identifiers.org/clinicaltrials/NCT02269423</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-e1798ec6564a0b93e2ff85c8adb805f0</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>VSV-ZEBOVNCT02269423</prefix><exact>NCT02280408</exact><postfix> October 20143 × 1</postfix><tags><tag><name>NCT02280408</name><uri>http://identifiers.org/clinicaltrials/NCT02280408</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-55a7bb037fed6bb8d46bda391f021119</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> vectorChAd3 EBOV GP</prefix><exact>NCT02289027</exact><postfix>October 20142.5 × 1</postfix><tags><tag><name>NCT02289027</name><uri>http://identifiers.org/clinicaltrials/NCT02289027</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-2677ef5c68eb3be1aacb621af488a9b0</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> vectorChAd3 EBOV GP</prefix><exact>NCT02267109</exact><postfix>October 20141 × 101</postfix><tags><tag><name>NCT02267109</name><uri>http://identifiers.org/clinicaltrials/NCT02267109</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-06e160186092bc1ce5147b10fc3c8bb0</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>al vaccinerVSV-ZEBOV</prefix><exact>NCT02296983</exact><postfix>NCT02283099NCT022874</postfix><tags><tag><name>NCT02296983</name><uri>http://identifiers.org/clinicaltrials/NCT02296983</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-6bbd3e8f311d9196af47d6747c5bb42a</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>VSV-ZEBOVNCT02296983</prefix><exact>NCT02283099</exact><postfix>NCT02287480November </postfix><tags><tag><name>NCT02283099</name><uri>http://identifiers.org/clinicaltrials/NCT02283099</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-9496166dfad97b83f0e5e910d4390797</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>T02296983NCT02283099</prefix><exact>NCT02287480</exact><postfix>November 20143 × 10</postfix><tags><tag><name>NCT02287480</name><uri>http://identifiers.org/clinicaltrials/NCT02287480</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-8d805bde0b33bdb627fcd6e0f28d3626</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>V GP and MVA-BN Filo</prefix><exact>NCT02313077</exact><postfix>December 2014ChAd3 a</postfix><tags><tag><name>NCT02313077</name><uri>http://identifiers.org/clinicaltrials/NCT02313077</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-b68e22bd5b32321e1298b7b7c48dbf5d</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>2014 outbreak strain</prefix><exact>NCT02326194</exact><postfix>December 20144 × 10</postfix><tags><tag><name>NCT02326194</name><uri>http://identifiers.org/clinicaltrials/NCT02326194</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-6c34a851ab973a5a477533f406c36f42</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>al vaccinerVSV-ZEBOV</prefix><exact>NCT02287480</exact><postfix>January 20153 × 105</postfix><tags><tag><name>NCT02287480</name><uri>http://identifiers.org/clinicaltrials/NCT02287480</uri></tag></tags><id>http://europepmc.org/articles/PMC5394635#europepmc-34ed995d1fa45a729af5cbb9f2d88d0b</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>